Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function

This study has been completed.
Information provided by:
Medical University Innsbruck Identifier:
First received: June 25, 2008
Last updated: February 9, 2009
Last verified: February 2009
The aim of the study is to investigate the effects of total intravenous anesthesia (TIVA; propofol, remifentanil) and balanced anesthesia (BAL; induction with propofol and fentanyl; maintenance of anesthesia with sevoflurane and nitrous oxide) on pulmonary function 30 minutes after emergence from the general anesthesia.

Condition Intervention Phase
Lung Function
Drug: propofol
Drug: remifentanil
Drug: fentanyl
Drug: Sevoflurane/Nitrous Oxide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Total Intravenous Anesthesia and Balanced Anesthesia on Postoperative Lung Function

Resource links provided by NLM:

Further study details as provided by Medical University Innsbruck:

Primary Outcome Measures:
  • FEV1 forced expiratory volume; FVC forced vital capacity [ Time Frame: preoperative, 30 minutes postoperative ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: June 2008
Study Completion Date: December 2008
Arms Assigned Interventions
Active Comparator: TIVA
patients receiving total intravenous anesthesia (TIVA)
Drug: propofol
propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
Drug: remifentanil
remifentanil 0,25mcg/kg/hour
Active Comparator: balanced
patients receiving balanced anesthesia
Drug: propofol
propofol 2mg
Drug: fentanyl
fentanyl 100mcg
Drug: Sevoflurane/Nitrous Oxide
maintenance of anesthesia with sevoflurane and nitrous oxide


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ASA 1-2
  • BMI normal

Exclusion Criteria:

  • lung disease
  • Nicotine abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00706277

TILAK Hospitals
Innsbruck, Austria, 6020
Sponsors and Collaborators
Medical University Innsbruck
Principal Investigator: Arnulf Benzer, MD TILAK Hospitals
  More Information

Responsible Party: Arnulf Benzer, TILAK A-6020 Innsbruck, Anichstr. 35 AUSTRIA Identifier: NCT00706277     History of Changes
Other Study ID Numbers: 2007-007161-25 
Study First Received: June 25, 2008
Last Updated: February 9, 2009
Health Authority: Austria: Agency for Health and Food Safety

Keywords provided by Medical University Innsbruck:
forced vital capacity
forced expired volume in 1 s

Additional relevant MeSH terms:
Nitrous Oxide
Central Nervous System Depressants
Physiological Effects of Drugs
Hypnotics and Sedatives
Anesthetics, Intravenous
Anesthetics, General
Analgesics, Opioid
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Platelet Aggregation Inhibitors
Anesthetics, Inhalation
Analgesics, Non-Narcotic processed this record on October 21, 2016